Neoantigen-based Melanoma-Poly-ICLC Vaccine

A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. (NCI Thesaurus)

YOU MAY ALSO LIKE

Neoangiogenesis

The formation of new or recent blood vessels. The vasculature network is critical to the development of neoplasms. As the tumor burden…

Neoadjuvant therapy

Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of…

NEO1 wt Allele

Human NEO1 wild-type allele is located within 15q22.3-q23 and is approximately 253 kb in length. This allele, which encodes neogenin, plays a…

NEO1 Gene

This gene plays a role in neural differentiation and cell cycle regulation.

NEO Gene

The NEO Gene confers resistance to the aminoglycoside antibiotic neomycin. NEO is widely used in genetic research because of the easily selectable…

Nemorubicin Hydrochloride

The hydrochloride salt form of nemorubicin, a morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450…